Phase 1 Study of JLP-2302 and JP-1366: PK and Safety in Healthy Volunteers
NCT07181538
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
55
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy
Interventions
DRUG:
JLP-2302
DRUG:
JP-1366
Sponsor
Onconic Therapeutics Inc.